Tags

Type your tag names separated by a space and hit enter

[HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering].
Nihon Rinsho. 1999 Dec; 57(12):2821-5.NR

Abstract

Several clinical prevention trials have firmly established that normalization of elevated serum cholesterol levels by 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) reductase inhibitors reduces the incidence of coronary events. Four HMG-CoA reductase inhibitors are now available for clinical use in Japan, and two others, under development, are expected to have strong lipid-lowing effects including triglycerides. Indeed, HMG-CoA reductase inhibitors exert direct anti-atherosclerotic effects, independently of their hypocholesterolemic properties. Recently many putative anti-atherogenic effects have been demonstrated, such as improvement in endothelial function, up-regulation of endothelial nitric oxide synthase activity, reduction of platelet thrombus formation, inhibition of monocyte chemotaxis or smooth muscle cell proliferation, and immunosuppressive effect. Moreover, HMG-CoA reductase inhibitors have shown the induction of cell death in vitro, by a pathway involving apoptosis. In conclusion, HMG-CoA reductase inhibitors may play more important roles, in addition to their well established efficacy and cost effectiveness in reducing hypercholesterolemia.

Authors+Show Affiliations

Department of Internal Medicine, Tsukuba Memorial Hospital.No affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

jpn

PubMed ID

10638219

Citation

Fujita, R, and T Matsushima. "[HMG-CoA Reductase Inhibitors: Anti-atherosclerotic Effects Other Than Lipid-lowering]." Nihon Rinsho. Japanese Journal of Clinical Medicine, vol. 57, no. 12, 1999, pp. 2821-5.
Fujita R, Matsushima T. [HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering]. Nihon Rinsho. 1999;57(12):2821-5.
Fujita, R., & Matsushima, T. (1999). [HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering]. Nihon Rinsho. Japanese Journal of Clinical Medicine, 57(12), 2821-5.
Fujita R, Matsushima T. [HMG-CoA Reductase Inhibitors: Anti-atherosclerotic Effects Other Than Lipid-lowering]. Nihon Rinsho. 1999;57(12):2821-5. PubMed PMID: 10638219.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering]. AU - Fujita,R, AU - Matsushima,T, PY - 2000/1/19/pubmed PY - 2000/2/26/medline PY - 2000/1/19/entrez SP - 2821 EP - 5 JF - Nihon rinsho. Japanese journal of clinical medicine JO - Nihon Rinsho VL - 57 IS - 12 N2 - Several clinical prevention trials have firmly established that normalization of elevated serum cholesterol levels by 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) reductase inhibitors reduces the incidence of coronary events. Four HMG-CoA reductase inhibitors are now available for clinical use in Japan, and two others, under development, are expected to have strong lipid-lowing effects including triglycerides. Indeed, HMG-CoA reductase inhibitors exert direct anti-atherosclerotic effects, independently of their hypocholesterolemic properties. Recently many putative anti-atherogenic effects have been demonstrated, such as improvement in endothelial function, up-regulation of endothelial nitric oxide synthase activity, reduction of platelet thrombus formation, inhibition of monocyte chemotaxis or smooth muscle cell proliferation, and immunosuppressive effect. Moreover, HMG-CoA reductase inhibitors have shown the induction of cell death in vitro, by a pathway involving apoptosis. In conclusion, HMG-CoA reductase inhibitors may play more important roles, in addition to their well established efficacy and cost effectiveness in reducing hypercholesterolemia. SN - 0047-1852 UR - https://www.unboundmedicine.com/medline/citation/10638219/[HMG_CoA_reductase_inhibitors:_anti_atherosclerotic_effects_other_than_lipid_lowering]_ L2 - https://medlineplus.gov/cholesterolmedicines.html DB - PRIME DP - Unbound Medicine ER -